ImmuLogic Pharmaceutical Corp. raised $10 million in apublic offering of 1 million shares that was declaredeffective Thursday.All the shares were purchased by Amerindo InvestmentAdvisors, of San Francisco, which now holds about 10percent of ImmuLogic's 17.1 million outstanding shares.The company has about $65 million in cash. ImmuLogic,of Waltham, Mass., filed to sell the shares on Aug. 16."As soon as we filed [Amerindo] expressed interest thewhole million," said Richard Small, ImmuLogic's vicepresident and chief financial officer. "Once Amerindocame in with the interest we just wanted to close thedeal."The stock sold for $10 per share. ImmuLogic's stock(NASDAQ:IMUL) closed Thursday at $10.63, up 13cents.The company is developing peptide immunotherapeutics.Allervax drugs targeting allergies are being developed incollaboration with Germany-based Hoechst MarionRoussel Inc. Allervax Cat is in a 270-patient study that'spart of the Phase III program for the product. AllervaxRagweed is in a Phase II/III study. _ Jim Shrine

(c) 1997 American Health Consultants. All rights reserved.